PIC Therapeutics is a technology company.
PIC Therapeutics has raised $40.0M across 2 funding rounds.
PIC Therapeutics has raised $40.0M in total across 2 funding rounds.
# PIC Therapeutics: A Biotechnology Pioneer, Not a Technology Company
Clarification: PIC Therapeutics is a biotechnology company, not a technology company in the traditional sense. While it employs advanced scientific techniques, it is fundamentally focused on drug discovery and development rather than software, hardware, or digital platforms.
PIC Therapeutics is a preclinical-stage biotechnology company developing small molecule therapeutics to treat cancer by modulating RNA translation[2]. The company targets what it calls the "master switch" of cancer signaling pathways—the Pre-Initiation Complex (PIC)—to selectively block oncogene protein production while preserving normal protein synthesis[1][3].
The company addresses a critical gap in oncology: existing cancer treatments often lose efficacy over time due to therapeutic resistance and tumor heterogeneity[3]. PIC's precision-based approach aims to simultaneously modulate multiple oncogenic drivers, potentially overcoming drug resistance and treating diverse cancer subtypes regardless of molecular variation[1][2]. Its initial focus is on breast cancer, particularly drug-resistant variants[1].
PIC Therapeutics was founded in 2016 and is based in Natick, Massachusetts[4]. The company emerged from recognition that cancer cells exhibit dysregulated protein synthesis—a vulnerability that could be exploited by targeting the molecular machinery that initiates mRNA translation[4].
The company's early trajectory included a $5 million Series Seed round led by Advent Life Sciences in April 2020, followed by a $35 million Series A round led by OrbiMed in October 2022, with participation from Lumira Ventures, Harrington Discovery Institute, and existing investors[1][4]. Dr. Katherine Bowdish was appointed Chief Executive Officer in August 2020, bringing leadership to guide the company's development[1].
PIC Therapeutics operates within a broader shift toward precision oncology and mechanism-first drug discovery. The company rides the trend of targeting fundamental cellular processes—in this case, protein synthesis—rather than relying solely on genetic mutations or surface markers. This approach is particularly timely as the field grapples with drug resistance and the complexity of treating heterogeneous tumors.
The timing is favorable: advances in structural biology and computational chemistry have made it feasible to design allosteric modulators targeting translation machinery, a target class that was previously considered "undruggable." Additionally, the oncology market continues to reward innovative approaches that address unmet needs in drug-resistant cancers[2][3].
PIC Therapeutics is positioned at an early but promising stage of development. As a preclinical-stage company, its immediate priorities are advancing its eIF4E program through preclinical studies and moving toward investigational new drug (IND) applications[2]. The company's ability to secure substantial Series A funding from top-tier biotech investors (OrbiMed) signals confidence in its scientific approach.
The company's future will depend on translating preclinical promise into clinical efficacy. If its translation-targeting approach proves effective in human trials, it could establish a new therapeutic modality for oncology. The broader trend toward targeting "undruggable" pathways and addressing drug resistance suggests that PIC's mechanism will remain relevant as the field evolves. Success would validate the hypothesis that modulating protein synthesis is a viable strategy for overcoming therapeutic resistance—a finding that could influence how the entire oncology field approaches cancer treatment.
PIC Therapeutics has raised $40.0M in total across 2 funding rounds.
PIC Therapeutics's investors include Advent Life Sciences.
PIC Therapeutics has raised $40.0M across 2 funding rounds. Most recently, it raised $35.0M Series A in October 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2022 | $35.0M Series A | Advent Life Sciences | |
| Apr 1, 2020 | $5.0M Seed | Advent Life Sciences |